Immune Characteristics of IgA Nephropathy With Minimal Change Disease

Immune Characteristics of IgA Nephropathy With Minimal Change Disease

Background: IgA nephropathy (IgAN) has a high degree of heterogeneity in clinical and pathological features. Among all subsets of IgAN, the pathogenesis of IgAN with minimal change disease (MCD-IgAN) remained controversial.Methods: We analyzed the clinical and pathological characteristics of MCD-IgA...

Full description

Bibliographic Details
Main Authors:	Huixian Li, Wanhong Lu, Haiyun Li, Xiaoling Liu, Xue Zhang, Liyi Xie, Ping Lan, Xiaoyang Yu, Yinjuan Dai, Xinfang Xie, Jicheng Lv
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-12-01
Series:	Frontiers in Pharmacology
Subjects:	MCD-IgAN galactose deficient IgA1 anti-glycan autoantibodies inflammation IgA nephropathy minimal change disease
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2021.793511/full

Similar Items

Pathogenic role of glycan-specific IgG antibodies in IgA nephropathy
by: Yan-feng Zhao, et al.
Published: (2017-09-01)

Characteristics of patients with coexisting IgA nephropathy and membranous nephropathy
by: Pei Chen, et al.
Published: (2018-10-01)

Current understanding of IgA antibodies in the pathogenesis of IgA nephropathy
by: Yoshihito Nihei, et al.
Published: (2023-04-01)

Clinical Relevance of Serum Galactose Deficient IgA1 in Patients with IgA Nephropathy
by: Jin Sug Kim, et al.
Published: (2020-11-01)

Aberrantly Glycosylated IgA1 in IgA Nephropathy: What We Know and What We Don’t Know
by: Yukako Ohyama, et al.
Published: (2021-08-01)

Galactose-Deficient IgA1 as a Candidate Urinary Marker of IgA Nephropathy
by: Yusuke Fukao, et al.
Published: (2022-06-01)

Glomerular Galactose-Deficient IgA1(KM55) Positive May Predict Poorer Prognosis in Coexisting Primary Membranous Nephropathy and IgA Nephropathy Patients
by: Wenrong Cheng, et al.
Published: (2022-12-01)

Inhibition of STAT3 Signaling Reduces IgA1 Autoantigen Production in IgA Nephropathy
by: Koshi Yamada, et al.
Published: (2017-11-01)

The Emerging Role of Complement Proteins as a Target for Therapy of IgA Nephropathy
by: Dana V. Rizk, et al.
Published: (2019-03-01)

An Update on the Current State of Management and Clinical Trials for IgA Nephropathy
by: Chee Kay Cheung, et al.
Published: (2021-06-01)

History of IgA Nephropathy Mouse Models
by: Batoul Wehbi, et al.
Published: (2021-07-01)

Alternative Complement Pathway Is Activated and Associated with Galactose-Deficient IgA1 Antibody in IgA Nephropathy Patients
by: Yen-Ling Chiu, et al.
Published: (2021-06-01)

Association Between Galactose-Deficient IgA1 Derived From the Tonsils and Recurrence of IgA Nephropathy in Patients Who Underwent Kidney Transplantation
by: Mayuko Kawabe, et al.
Published: (2020-09-01)

IgA Nephropathy Associated with IgA Vasculitis Coexisting with Focal Segmental Glomerulosclerosis Tip Variant
by: Zitlali Guadalupe Paulín Zepeda, et al.
Published: (2023-07-01)

IgA Vasculitis and IgA Nephropathy: Same Disease?
by: Evangeline Pillebout
Published: (2021-05-01)

Concurrent IgA Nephropathy and Membranous Nephropathy, Is It an Overlap Syndrome?
by: Jia-Wei He, et al.
Published: (2022-03-01)

IgA Nephropathy: Pleiotropic impact of Epstein-Barr virus infection on immunopathogenesis and racial incidence of the disease
by: Jiri Mestecky, et al.
Published: (2023-02-01)

Corrigendum: Concurrent IgA nephropathy and membranous nephropathy, is it an overlap syndrome?
by: Jia-Wei He, et al.
Published: (2023-06-01)

New Treatment Strategies for IgA Nephropathy: Targeting Plasma Cells as the Main Source of Pathogenic Antibodies
by: Dita Maixnerova, et al.
Published: (2022-05-01)

Pathogenesis of IgA Nephropathy: Current Understanding and Implications for Development of Disease-Specific Treatment
by: Barbora Knoppova, et al.
Published: (2021-09-01)

Comparative study on clinicopathological features and prognosis of IgA vasculitis nephritis and IgA nephropathy in children
by: Yan Lv, et al.
Published: (2023-08-01)

Efficacy and safety of artesunate for patients with IgA nephropathy: a study protocol for a multicenter, double-blind, randomized, placebo-controlled trial
by: Qi Chen, et al.
Published: (2022-05-01)

Severe Adverse Effects Associated With Corticosteroid Treatment in Patients With IgA Nephropathy
by: Qingqing Cai, et al.
Published: (2017-07-01)

Predictors of prognosis in IgA nephropathy
by: Yasuhiko Tomino
Published: (2012-10-01)

Mucosal Immune System Dysregulation in the Pathogenesis of IgA Nephropathy
by: Toshiki Kano, et al.
Published: (2022-11-01)

Cyclosporine A combined with medium/low dose prednisone in progressive IgA nephropathy
by: Lin Xu, et al.
Published: (2014-08-01)

An Update on Current Therapeutic Options in IgA Nephropathy
by: Regina Shaoying Lim, et al.
Published: (2024-02-01)

Associations between Biomarkers of Complement Activation, Galactose-Deficient IgA1 Antibody and the Updated Oxford Pathology Classification of IgA Nephropathy
by: Yun-Ting Juan, et al.
Published: (2022-07-01)

Monitoring Immune Responses in IgA Nephropathy: Biomarkers to Guide Management
by: Haresh Selvaskandan, et al.
Published: (2020-10-01)

The pathogenesis of COVID-19-induced IgA nephropathy and IgA vasculitis: A systematic review
by: Hareem Farooq, MBBS, et al.
Published: (2022-02-01)

Celiac Disease-Type Tissue Transglutaminase Autoantibody Deposits in Kidney Biopsies of Patients with IgA Nephropathy
by: Rakel Nurmi, et al.
Published: (2021-05-01)

Colocalization of IgG and IgA Heavy Chains with Kappa and Lambda Light Chains in Glomerular Deposits of IgA Nephropathy Patients Using High-Resolution Confocal Microscopy and Correlation with Oxford MEST-C Scores
by: Dana V. Rizk, et al.
Published: (2023-11-01)

Orange-derived and dexamethasone-encapsulated extracellular vesicles reduced proteinuria and alleviated pathological lesions in IgA nephropathy by targeting intestinal lymphocytes
by: Wang Zhang, et al.
Published: (2022-08-01)

Tetrandrine inhibits the proliferation of mesangial cells induced by enzymatically deglycosylated human IgA1 via IgA receptor/MAPK/NF-κB signaling pathway
by: Wencheng Xu, et al.
Published: (2023-06-01)

Increased plasma sVCAM-1 is associated with severity in IgA nephropathy
by: Zhu Li, et al.
Published: (2013-01-01)

Characteristics of renal pathology and coagulation function in IgA nephropathy and IgA vasculitis associated nephritis
by: Yinhong Wang, et al.
Published: (2024-01-01)

Is There a Role for Gut Microbiome Dysbiosis in IgA Nephropathy?
by: Renato C. Monteiro, et al.
Published: (2022-03-01)

Glucocorticoids Reduce Aberrant O-Glycosylation of IgA1 in IgA Nephropathy Patients
by: Petr Kosztyu, et al.
Published: (2018-03-01)

Medium from mesangial cells incubated with aggregated IgA1 from IgA nephropathy patients reduces podocyte adhesion through activation of the renin angiotensin system
by: C Wang, et al.
Published: (2011-12-01)

Characterization of IgA Deposition in the Kidney of Patients with IgA Nephropathy and Minimal Change Disease
by: Won-Hee Cho, et al.
Published: (2020-08-01)